# contract manufacturing

China’s Taurine Champion Warns of More Than 50% Profit Drop as Prices and Demand Slip

Yong'an Pharmaceutical, a leading Chinese taurine producer, expects net profit for 2025 to fall between RMB 18.19m and RMB 27.05m, down more than half from the prior year. The drop reflects weaker prices and sales in the taurine market; the company plans a RMB 50m capital injection into its subsidiary to develop downstream capabilities, even as regulators issued a warning over disclosure lapses.